Phibro continues to win over investors 6 months after IPO

Even in the midst of a rocky week on the public markets, shares of Wall Street newcomer Phibro Animal Health ($PAHC) continued to ride a wave of positive analyst notes and overall investor enthusiasm for the animal health industry. The Teaneck, NJ-based company markets a range of antibiotics, vaccines and specialty nutritional products to the livestock industry. Last Monday's 5.34% gain made the company one of the best performers in the Russell 2000--with 333,474 shares traded, versus an average daily volume of 92,043--according to Phibro, which priced its April IPO at $15 a share, traded to a high of $26.19 during the week before settling at $23.45. Article

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…